Strom11206

488 views

Published on

Published in: Business, Technology
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
488
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
25
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Strom11206

  1. 1. Introduction to Pharmacoepidemiology Methods • Background re: Epi Methods • Present • Future CCEB
  2. 2. Options in Research Design • Analytic Studies –Experimental Study –Cohort Study –Case-Control Study • Descriptive Studies –Analyses of Secular Trends –Case Series –Case Reports CCEB
  3. 3. Case-Control Studies Disease Factor Cohort Studies Present (cases) Absent (controls) Present (exposed) A B Absent (not exposed) C D
  4. 4. Prospective vs. Retrospective Studies Events Under Study Prospective Study Retrospective Study Time CCEB
  5. 5. Pharmacoepidemiology: Unique Characteristics 1. A large population needs to be studied 2. Randomized clinical trials are unlikely to be productive 3. Answers often must be obtained very quickly CCEB
  6. 6. CCEB
  7. 7. Hypothesis Generating Hypothesis Strengthening Hypothesis Testing CCEB
  8. 8. Current Status of Pharmacoepidemiology CCEB
  9. 9. Data Sources for Pharmacoepidemiology Studies • Spontaneous case reports of adverse reactions • Aggregate population-based data sources • Computerized collections of data from organized medical care programs • Data collected for pharmacoepi on an ongoing basis • Existing data collected as part of other ad hoc studies • Data collected de novo CCEB
  10. 10. Spontaneous Reports of Adverse Reactions: Advantages • Incorporates all drugs • Incorporates all prescribers • Relatively inexpensive CCEB
  11. 11. Spontaneous Reports of Adverse Reactions: Disadvantages • Under- or over-ascertainment • Under-reporting • External events can change ascertainment or reporting • No denominators CCEB
  12. 12. Using Vital Statistics and Sales Data to Perform Analyses of Secular Trends • Advantages: Fast and relatively inexpensive • Disadvantages: -Cannot differentiate among alternative exposures with consistent trends -Findings can be artifactual CCEB
  13. 13. Computerized Collections of Billing Data: Sources of Data Provider: Pharmacy Provider: Hospital Provider: Physician CCEB Payor Data User
  14. 14. Computerized Collections of Medical Billing Data: Advantages • Size • Cost • Complete • Can be population-based • Can include outpatient drugs and diseases • No recall or interviewer bias CCEB
  15. 15. Computerized Collections of Medical Billing Data: Disadvantages • Uncertain validity of diagnosis data • No information on some potential confounding variables • Only includes illnesses severe enough to come to medical attention • Some results may not be generalizable, e.g., on health care utilization CCEB
  16. 16. Medical Records Databases (e.g., GPRD, THIN) Advantages Disadvantages • Completeness of data • GP data only • Quality of data • Completeness of outcomes uncertain • Easy access to primary • May be a skewed medical records group of docs CCEB
  17. 17. Data Collected for PMS on an Ongoing Basis: BCDSP Hospital-Based Surveillance Advantages • Denominator known • Quality of data CCEB Disadvantages • Inpatient drugs only • Short-term effect only • Common effects only • Old: data cannot be used to study new drugs
  18. 18. Data Collected for PMS on an Ongoing Basis:Drug (Slone) Epidemiology Unit Advantages Disadvantages • Study of rare illnesses • Hospitalized dzs only • Quality of data • Denominator unknown • ?Validity of rx data • Cannot be used to study new drugs CCEB
  19. 19. Existing Data Collected as Part of Other Ad Hoc Studies • Advantages: Cost, speed • Disadvantages: Incomplete data, lack of quality control CCEB
  20. 20. Data Collected De Novo For the Study Being Conducted • Advantage: Completely tailored data • Disadvantages: Cost, time delay CCEB
  21. 21. Prescription Event Monitoring Advantages Disadvantages • Large population • Participation rate • Quality of data • Cost • Time delay • Limited numbers of drugs CCEB
  22. 22. Future of Pharmacoepidemiology CCEB
  23. 23. Future Scientific Developments • Applications of new epi methods • Drug utilization review programs • Evaluation of causality in case reports • Systematic screening for ADRs • Appropriate role of data mining • Studies of beneficial drug effects • Studies of pharmacoeconomics • Studies to aid in individualizing drug therapy • Quality of life studies CCEB • Large simple trials
  24. 24. Future Logistic Approaches • More data bases • US Medicare • Pharmacy-based surveillance • Poison control centers • Others? CCEB
  25. 25. Molecular Pharmacoepidemiology • Use of molecular methods to measure genetics in traditional case-control studies • Use of molecular methods to measure individuals’ probability of drug response CCEB
  26. 26. New Structures Which Will be Affecting the Future of Pharmacoepidemiology CCEB • Hospital initiatives • CERTs • Patient Safety Initiatives • CPOE • HIPAA • Risk management • Medicare Part D • IOM!?!?
  27. 27. Key Problem of “Historical” Pharmacoepidemiology • Adverse drug events are the most common iatrogenic causes of patient injuries • Most are the result of an exaggerated but otherwise usual pharmacological effect of the drug • Yet, historically these have been ignored by pharmacoepidemiology, as they do not represent a focus of commercial and regulatory interest CCEB
  28. 28. Potential Threats to the Continued Development of Pharmacoepidemiology • Scientific errors • Funding limitations • Absence of training programs • Corruption by studies conducted purely for marketing purposes • Inappropriate use in litigation CCEB

×